Figure 4 | British Journal of Cancer

Figure 4

From: Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

Figure 4

Modulation of VEGFR2 by VEGF in vivo. The VEGF121 (15 μg/mouse) was administered via tail vein in mice, and their lungs harvested at the indicated time points. Values represent the ratio of VEGFR2 to β-tubulin as determined by densitometry and normalised to vehicle-treated mice. Human umbilical vein endothelial cells immunoprecipitated using anti-VEGFR2 antibody from 350 μg protein were used as controls.

Back to article page